John Hardy, PhD, University College London, London, UK, discusses how genome-wide association studies (GWAS) have increased our understanding of Alzheimer’s disease. The use of GWAS has increased our knowledge of the biology of Alzheimer’s disease and shed light on pathways that have been previously neglected, for example, microglia and lipid metabolism. GWAS can also be utilized to identify patients at high risk of developing Alzheimer’s disease before the onset of clinical symptoms. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
John Hardy occasionally consults for Eisai and is on the SAB of the biotech Ceracuity.